CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
therapy in participants with metastatic castration-resistant prostate cancer (mCRPC) comprising 2 phases: a Phase 1 Dose Escalation...
Phase 1, Phase 2
Portland, Oregon, United States and 9 other locations
pharmacodynamic (PD), and the preliminary efficacy of JANX007 administered as a single agent in adults with metastatic castration-resistant prostate...
Phase 1
Portland, Oregon, United States and 10 other locations
The purpose of this study is to evaluate the effectiveness of CAN-2409 immunotherapy in patients undergoing active surveillance for localized prostate...
Phase 2
Portland, Oregon, United States and 22 other locations
Phase 1b study to assess the combination of ARV-110 and abiraterone in patients with metastatic prostate cancer with rising PSA val...
Phase 1
Portland, Oregon, United States and 17 other locations
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic the...
Phase 1, Phase 2
Portland, Oregon, United States and 53 other locations
radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a ...
Phase 3
Portland, Oregon, United States and 72 other locations
with abiraterone acetate plus prednisone has on the patient and the prostate cancer. Abiraterone acetate plus prednisone are drugs ...
Phase 1, Phase 2
Portland, Oregon, United States and 2 other locations
All patients will be required to have a biopsy of a metastatic tumor deposit at study entry. Pembrolizumab will be administered at a dose of 200 mg a...
Phase 2
Portland, Oregon, United States
Pembrolizumab will be administered at a dose of 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Enzalutamide will be administer...
Phase 2
Portland, Oregon, United States
This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, ...
Phase 4
Portland, Oregon, United States
Clinical trials
Research sites
Resources
Legal